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 I. INTRODUCTION 
 
A number of studies have shown that serum uric acid (SUA) plays a 
role in the development of cardiovascular morbidity in the general 
population,1-4 as well as in patients with hypertension, 5-7 type 2 diabetes,8 
and cardiac or vascular diseases.9-12  A meta-analysis of data taken from 8 
trials that were performed on hypertensive patients showed that each 
standard deviation (SD) increment in SUA entails an augmentation of 
cardiovascular risk that equals what is observed for similar changes in blood 
pressure or total cholesterol.13 However, the independent role of SUA as a 
risk factor has been undergoing debate for years. In fact, mild hyperuricema 
is often a concomitant finding of obesity, lipid abnormalities, and insulin 
resistance, all of which are components of the metabolic syndrome (MS). 
Accordingly, in some studies on white as well as Asian populations, the 
direct relationship that is observed between uric acid and cardiovascular 
mortality weakens or disappears after adjusting for confounding factors.14-16 
Several pathophysiological mechanisms linking SUA to 
cardiovascular damage at the cellular and tissue level have been proposed, 
including proliferation of vascular smooth muscle cells,17 stimulation of the 
inflammatory pathway, 18 and possible prothrombotic effects mediated by 
platelet activation. 19 In addition, uric acid has proved to be an excellent 
 marker for tissue ischemia and endothelial dysfunction,11,20 and it has been 
shown to play a role in the development of atherosclerotic lesions.21 
The presence of subclinical hypertensive organ damage signals a 
condition of increased risk for cardiovascular and renal morbidity and 
mortality. Thus, the search for left ventricular hypertrophy (LVH), carotid 
atherosclerosis, and microalbuminuria, which likely reflect both the severity  
of blood pressure load and other nonhemodynamic risk factors, is currently 
recommended as part of global risk assessment.22  Because the role of SUA 
in the development of cardiovascular disease is receiving growing attention, 
a better understanding of its relationship  with subclinical hypertensive target 
organ damage(TOD) may  help clarify the pathophysiological mechanism(s) 
underlying this association. The present study was therefore performed to 
evaluate the association between SUA levels and the presence of preclinical 
organ damage in newly or recently detected hypertensive patients. 
 II. AIM OF THE STUDY 
 
The aim of this study is to evaluate the correlation between serum uric 
acid levels and the presence of preclinical target organ damage in 
hypertensive population. 
         Target organ damage is assessed by                                                                               
                               a) Microalbuminuria, 
                               b) Echocardiography,                                                                         
   c) Fundus examination. 
 III. REVIEW OF LITERATURE 
Hypertension doubles the risk of cardiovascular diseases, including 
coronary heart disease (CHD), congestive heart failure (CHF), ischemic and 
hemorrhagic stroke, renal failure, and peripheral arterial disease. 
Hypertension is often associated with additional cardiovascular disease risk 
factors, and the risk of cardiovascular disease increases with the total burden 
of risk factors.23 
MECHANISMS OF HYPERTENSION  
1.    INTRAVASCULAR VOLUME 
The initial elevation of blood pressure in response to vascular volume 
expansion is related to an increase of cardiac output; however, over time, 
peripheral resistance increases and cardiac output reverts toward normal. 
The mechanism for the “pressure-natriuresis” phenomenon may 
involve a subtle increase of glomerular filtration rate, decreased absorbing 
capacity of the renal tubules, and possibly hormonal factors such as atrial 
natriuretic factor.23  
 
 
 AUTONOMIC NERVOUS SYSTEM 
The autonomic nervous system maintains cardiovascular homeostasis 
via pressure, volume and chemoreceptor signals. Adrenergic reflexes 
modulate blood pressure over the short term, and adrenergic function, in 
concert with hormonal and volume-related factors, contributes to the long-
term regulation of arterial pressure.23 
RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM 
The renin-angiotensin-aldosterone system(figure 1) contributes to the 
regulation of arterial pressure primarily via the vasoconstrictor properties of 
angiotensin II and the sodium-retaining properties of aldosterone. 
Angiotensin II is a potent pressor substance, the primary trophic factor for 
the secretion of aldosterone by the adrenal zona glomerulosa, and a  potent  
mitogen stimulating vascular smooth-muscle cell and myocyte growth 
factor. Independent of its hemodynamic effects, Angiotensin II may play a 
role in the pathogenesis of atherosclerosis through a direct cellular action on 
the vessel wall.23   
Aldosterone also has effects on nonepithelial targets. Independent of a 
potential effect on blood pressure, aldosterone may also play a role in 
cardiac hypertrophy and CHF. 
 
         
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 1 : Renin Angiotensin Aldosterone System. 
 
Pathologic patterns of left ventricular geometry have also been 
associated with elevations of plasma aldosterone concentration in patients 
with essential hypertension, as well as in patients with primary 
aldosteronism. 
 
 
 PATHOLOGIC CONSEQUENCES OF HYPERTENSION  
1.  HEART 
Hypertensive heart disease is the result of structural and functional 
adaptations leading to left ventricular hypertrophy, diastolic dysfunction, 
CHF, abnormalities of blood flow due to atherosclerotic coronary artery 
disease and microvascular disease and cardiac arrhythmias. 
Diastolic dysfunction is an early consequent of hypertension- related 
heart disease and is exacerbated by left ventricular hypertrophy and 
ischemia. 
2.  BRAIN 
Hypertension is an important risk factor for brain infarction and 
haemorrhage. The incidence of stroke rises progressively with increasing 
blood pressure levels, particularly systolic blood pressure in individuals >65 
years.23 
 Hypertension is also associated with impaired cognition in an aged 
population. Hypertensive encephalopathy is related to failure of 
autoregulation of cerebral blood flow at the upper pressure limit, resulting in 
vasodilation and hyperperfusion. Untreated hypertensive encephalopathy 
may progress to stupor, coma, seizures and death within hours. 
 
 3.  KIDNEY 
Hypertension is a risk factor for renal injury and ESRD. The increased 
risk associated with high blood pressure is graded, continuous, and present 
throughout the entire distribution of blood pressure above optimal. Renal 
risk appears to be more closely related to systolic than to diastolic blood 
pressure. 
The atherosclerotic, hypertension-related vascular lesions in the 
kidney primarily affect the preglomerular arterioles, resulting in ischemic 
changes in the glomeruli and postglomerular structures. Glomerular 
pathology progresses to glomerulosclerosis, and eventually the renal tubules 
may also become ischemic and gradually atrophic. 
Clinically macroalbuminuria (random urine albumin/creatinine ratio > 
300 mcg/mg or microalbuminuria (a random urine albumin / creatinine ratio 
30-300 mcg/mg) are early markers of renal injury.23 
4.  PERIPHERAL ARTERIES 
Hypertensive patients with arterial disease of the lower extremities are 
at increased risk for future cardiovascular disease. The ankle-brachial index 
is a useful approach for evaluating Peripheral Arterial Disease and is defined 
as the ratio of noninvasively assessed ankle to brachial (arm) systolic blood 
 pressure. An ankle-brachial index <0.90 is considered diagnostic of 
Peripheral Arterial Disease. 
 
 
 
 
 
 
 
 
FIGURE 2 : Complications of Hypertension. 
 
DEFINING HYPERTENSION 
From an epidemiologic perspective, there is no obvious level of blood 
pressure that defines hypertension. The multiple Risk Factor Intervention 
Trial (MRFIT), which included >350,000 male participants demonstrated a 
continuous and graded influence of both systolic and diastolic blood pressure 
on CHD mortality. 
Cardiovascular disease risk doubles for every 20-mmHg increase in 
systolic and 10-mrnHg increase in diastolic pressure. Among older 
 individuals, systolic blood pressure and pulse pressure are more powerful 
predictors of cardiovascular disease than diastolic blood pressure.23,24 
CRITERIA 
Recommended criteria for a diagnosis of hypertension are average 
awake blood pressure > 135/85 mmHg and asleep blood pressure >120/75 
mmHg. These levels approximate a clinic blood pressure of  
> 140/90 mm Hg.23,24 
Classification of Blood Pressure for Adults 
 Based on the seventh report of JOINT NATIONAL COMMITTEE on 
prevention, detection, evaluation and treatment of hypertension  
(JNC 7). 
Table — I 
JNC VII Classification 
Blood Pressure 
Classification Systolic, mmHg 
Diastolic, 
mmHg 
Normal <120 and <80 
Prehypertension  120-139 or 80-89 
Stage 1 hypertension 140-159 or 90-99 
Stage 2 hypertension > 160 or > 100 
Isolated systolic hypertension > 140 And < 90 
 
 ACCURATE BLOOD PRESSURE MEASUREMENT  
 The accurate measurement of BP is the sine qua non for successful 
management. The equipment whether aneroid, mercury or electronic, should 
be trained and regularly retrained in the standardized technique, and the 
patient must be properly prepared and positioned. The auscultatory method 
of BP measurement should be used.  
Persons should be seated quietly for at least 5 minutes in a chair 
(rather than on an examination table), with feet on the floor, and arm 
supported at heart level. Caffeine, exercise and smoking should be avoided 
for at least 30 minutes prior to measurement. Measurement of BP in the 
standing position is indicated periodically, especially in those who report 
symptoms consistent with reduced BP on standing. An appropriately sized 
cuff (cuff bladder encircling at least 80% of the arm) should be used to 
ensure accuracy. At least two measurements should be made and the average 
recorded. 
For manual determinations, palpated radial pulse obliteration pressure 
should be used to estimate SBP; the cuff should then be inflated 20 to 30 mm 
Hg above this level for the auscultatory determinations; the cuff deflation 
rate for auscultatory readings should be 2 mm Hg per second.  SBP is the 
point at which the first of two or more korotkoff sounds is heard (onset of 
 phase I), and the disappearance of Korotkoff sound (onset of phase5) is used 
to define DBP. 
In Certain conditions like Aortic Regurgitation, the diastolic BP will 
be 0 mm Hg and the appearance of muffled sound is taken as diastolic BP. 
Care should be taken while measuring BP in elderly patients as there will be 
auscultatory gap. 
Recommendations for Follow-Up Based on Initial Blood Pressure 
Measurements for Adults without Acute End Organ Damage (JNC-7). 
Initial Blood Pressure,
 mm Hg* 
Follow –Up Recommended+ 
Normal Recheck in 2 years 
Prehypertension Recheck in 1 Year 
Stage 1  Hypertension Confirm within 2 Months# 
Stage 2  Hypertension Evaluate or refer to source of care within 1 
month.For those with higher pressures 
(eg.>180/110mm Hg) evaluate and treat 
immediately or within 1 week depending on 
clinical situation and complications. 
 
* If systolic and diastolic categories are different, follow recommendations for  shorter  
time follow- up (e.g, 160/86 mm Hg should be evaluated or referred to source of care 
within 1 month) 
+  Modify the scheduling of follow up according to reliable information about past  BP 
measurements, cardiovascular risk factors or target organ damage. 
#  Provide advice about lifestyle modifications. 
 
 
 
 The key messages of JNC- VII are : 24 
¾ In those older than age 50, systolic blood pressure of greater than 140 
mm Hg is a more important cardiovascular disease (CVD) risk factor 
than diastolic BP. 
¾ Beginning at 115/75 mm Hg, CVD risk doubles for each increment of 
20/10 mm Hg. 
¾ Those who are normotensive at 55 years of age will have a 90% life 
time risk of developing hypertension. 
¾ Prehypertensive individuals require health promoting lifestyle 
modifications to prevent the progressive rise in blood pressure and 
Cardio-vascular disease. 
¾ For uncomplicated hypertension, thiazide diuretic should be used in  
drug treatment for  most patients,  either alone or combined with drugs 
from other classes. 
¾ Two or more antihypertensive drugs will be required to achieve  goal 
BP (<140/90 mm Hg or <130 mm Hg) for  patients with diabetes  and 
chronic kidney disease. 
¾ For patients whose BP is more than 20 mm Hg above the systolic BP 
goal or more than 10  mm above  the diastolic BP goal, initiation  of 
therapy using two agents, one of which usually will be a thiazide 
diuretic, should be considered. 
 CLINICAL DISORDERS OF HYPERTENSION 
1.  ESSENTIAL HYPERTENSION 
2.  METABOLIC SYNDROME 
3.  RENOVASULAR HYPERTENSION 
4  PRIMARY ALDOSTERONISM 
5. CUSHING’S SYNDROME 
6. PHEOCHROMOCYTOMA 
7. MISCELLANEOUS CAUSES OF HYPERTENSION  
Obstructive sleep apnea, Coarctation of the aorta, acromegaly, 
hypercalcemia, both hypo and hyper thyroidism. 
8. MONOGENIC HYPERTENSION 
ESSENTIAL HYPERTENSION 
Essential hypertension tends to be familial and is likely to be the non-
sequence of an interaction between environmental and genetic factors. The 
prevalence of essential hypertension increases with age. In the majority of 
patients with established hypertension, peripheral resistance  is increased and 
cardiac output is normal or decreased; however, in younger patients with 
mild or labile hypertension, cardiac output may be increased and peripheral 
resistance may be normal. 
 High-renin patients may have a vasoconstrictor form of hypertension, 
whereas low renin patients may have a volume-dependent hypertension.23 
URIC ACID METABOLISM 
Uric acid is the final breakdown product of purine degradation in 
humans. Urates, the ionized forms of uric acid, predominate in plasma 
extracellular fluid and synovial fluid, with 98% existing as monosodium 
urate at pH 7.4.25 
The pH of urine greatly influences the solubility of uric acid. 
Although purine nucleotides are synthesized and degraded in all tissues, 
urate is produced only in tissues that contain xanthine oxidase, primarily the 
liver and small intestine. Urate production varies with the purine content of 
the diet and the rates of purine biosynthesis, degradation, and  salvage. 
Normally, two-third to three-fourth of urate is excreted by kidney, and most 
of the remainder is eliminated through  the intestine. 
METABOLISM 
The kidneys clear urate from the plasma and maintain physiologic 
balance by utilizing specific organic anion transporters (OATs) including 
urate transporter 1 (URATI) and human uric acid transporter (hUAT). 
URATI and other OATs carry urate into the tubular cells from the apical side 
 of the lumen. Once inside the cell, urate must pass to the basolateral side of 
the lumen in a process controlled by the voltage-dependent carrier hUAT. 
Until recently, component model has been used to describe the  renal 
handling of urate / uric acid. The methods are  
(l) Glomerular filtration, 
(2)  Tubular reabsorption, 
(3)  Secretion, and 
(4)  Postsecretory reabsorption.  
URAT1 is a novel transporter expressed at the apical brush border of 
the proximal nephron. . Uric acid compounds directly inhibit URAT1 on the 
apical side of the tubular cell (so called cis-inhibition).25 
The total-body urate pool is the net result between urate production and 
excretion 
Urate production is influenced by dietary intake of purines and the 
rates of de novo biosynthesis of purines from nonpurine precursors, nucleic 
acid turnover and salvaging phosphoribosyltransferase activities. The formed 
urate is normally excreted by urinary and intestinal routes. Hyperuricemia 
can be caused by increased production, decreased excretion, or a 
 combination of mechanisms. When hyperuricemia exists, urate can 
precipitate and deposit in tissues as tophi. 
HYPERURICEMIA 
Hyperuricemia is defined as a plasma (or serum) urate 
concentration > 6.0 mg/dl in females and > 7.0 mg/dl in males.25,26,27 
CAUSES OF HYPERURICEMIA 
Hyperuricemia may be classified as primary or secondary depending 
on whether the cause is innate or is the result of an acquired disorder. 
However, it is more useful to classify hyperuricemia in relation to the 
underlying pathophysiology, i.e., whether it results from increased 
production, decreased excretion, or a combination of the two. 
 Classification of hyperuricemia by pathophysiology 
Urate Overproduction 
Primary idiopathic Myeloproliferative diseases Rhabdomyolysis 
HPRT deficiency  Polycythemia vera Exercise 
PRPP synthetase  
Overactivity  
Psoriasis Alcohol 
Hemolytic Processes Paget’s disease Obesity 
Lymphoproliferative 
diseases 
Glycogenosis III, V, and 
VII 
Purine – rich diet 
Decreased Uric Acid Excretion 
Primary idiopathic  Starvation ketosis Drug ingestion 
Renal insufficiency  Berylliosis  Salicylates 
(>2g/d) 
Polycystic kidney  Sarcoidosis Diuretics 
Diabetes insipidus  Lead intoxication Alcohol  
Acidosis Hypothyroidism Ethambutol 
Lactic acidosis Toxemia of pregnancy  Pyrazinamide  
Diabetic ketoacidosis Bartter’s syndrome Nicotinic acid 
Down’s syndrome Cyclosporine  
 
 
Combined Mechanism 
Glucose -6- phosphatase 
deficiency  
Fructose – 1 phosphate aldolase 
deficiency  
Alcohol
Shock  
Note : HPRT, hypoxanthine phosphoribosyltransferase, PRPP, phosphoribosylpyrophosphate. 
 
 HISTORY OF URIC ACID AND HYPERTENSION 
The concept that uric acid may be involved in hypertension is not a 
new one. In fact, in the paper published in 1879 that originally described  
essential hypertension, Frederick Akbar Mohamed noted that many of his 
subjects came from gouty families. He hypothesized that uric acid might be 
integral to the development of essential hypertension.28 
Ten years later, this hypothesis re-emerged when Haig29 proposed  
low-purine diets as a means to prevent hypertension and vascular disease. In 
1909, the French academician Henri Huchard noted that renal 
arteriolosclerosis (the histologic lesion of hypertension) was observed in 
three groups: those with gout, those with lead poisoning, and those who have 
a diet enriched with fatty meat. All of these groups are associated  with 
hyperuricemia.30 
The association between elevated serum uric acid and hypertension 
was observed and reported repeatedly in the 1950s to 1980 but received 
relatively little sustained attention because of lack of a mechanistic 
explanation.31-33 
Twenty-five to 40% of adult patients with hypertension have 
hyperuricemia (> 6.5 mg/dl), and this number increase dramatically when 
serum uric acid in the high-normal range is included.34,35  In pre-eclampsia, 
 the correlation between elevated serum uric acid and hypertension is >70%.36 
Despite these observations, the lack of a causal mechanism led to mild 
elevations of serum uric acid being largely ignored in medial practice. 
The strength of the relationship between uric acid level and 
hypertension decreases with increasing patient age and duration of 
hypertension, suggesting that uric acid may be most important in younger 
subjects with early-onset hypertension.33  
 Cross – sectional studies have consistently noted that more than a 
quarter of patients with untreated hypertension have elevated SUA.34,37 SUA 
levels have also been associated cross–sectionally with BP33,38,39 and 
longitudinally with hypertension incidence 42-44,47,48 and future increases in 
BP.45 
MILD HYPERURICEMIA IN THE RAT, AN ANIMAL MODEL FOR 
ESSENTIAL HYPERTENSION 
  The study of mild hyperuricemia required an animal model before the 
lack of any mechanistic detail that had plagued the hypothesis over 100 years 
could be addressed. 
 In the late 1990s, Johnson and Colleagues46 developed a model using a 
pharmacologic inhibitor of urate oxidase, oxonic acid that allows the study 
 of sustained mild hyperuricemia. When fed 2% oxonic acid in their standard 
diet Sprague –Dawley rats have an increase of mean serum  uric acid  
concentrations from 0.5 to 1.4 g/dl to 1.7 to 3.0 mg/dl. During a 7wk 
treatment period, systolic BP increases an average of 22 mm Hg. The 
increase in BP can be prevented entirely by the co-administration  of the 
xanthine oxidase inhibitor allopurinol or by the uricosuric  agent 
benziodarone,  indicating linearly related to the rise in uric acid (r = 0.77). 
Histologic evaluation of the renal tissue of the hyperuricemic 
hypertensive rats reveals an expansion of the vascular smooth muscle and 
narrowing of the lumina of the afferent arterioles. It is interesting that the 
development of arteriolosclerosis can be prevented using allopurinol to 
control uric acid levels; however, hydrochlorothiazide, which normalizes BP 
without lowering serum uric acid, does not prevent the development of 
arterioloscierosis, indicating that uric acid, not hypertension is the causative 
stimulus.17,37 
These experimental results indicate that mild hyperuricemia induces 
renal inflammation, activation of the renin-angiotensin system, and 
downregulation of nitric oxide production, all of which are potentially 
important pathways that lead to uric acid-mediated hypertension. In short, 
mild hyperuricemia leads to an irreversible salt–sensitive hypertension over 
time.  
 Recent in vitro studies also have elucidated the possible mechanism  
of uric acid mediated arteriolosclerosis. Primary human vascular smooth 
muscle cells (HVSMC) are induced to proliferate by addition of uric acid to 
the growth medium in a dose-dependent manner.49 The  human smooth 
muscle cells express the urate-transport channel URATI as evidenced by 
both Northern and Western analyses. Consistent with this observation, 
cultured HVSMC rapidly take up C-urate, and blockade of this uptake by 
probenecid attenuates the uric acid-mediated induction of proliferation in a 
dose-dependent manner.50 Signaling studies have revealed further the 
possible mechanism by which urate uptake leads to HVSMC 
proliferation.49,51,52 
The effect of uric acid on vascular smooth muscle cells (VSMC) 
Uric acid is taken up through the probenecid-sensitive urate-transport 
channel URATI. This leads to mitogen activated protein kinase activation 
and extracelluar signal–regulated kinase 1 and 2 (Erk ½) phosphorylation. In 
turn, transcription factors NF-β(nuclear transcription factor) and AP1 are 
activated leading to increased cyclo-oxygenase-2(COX-2) expression and 
activity. The COX-2 product Thromboxane A2 mediates increased 
expression and elaboration of platelet derived growth factor (PDGF) and 
monocyte chemoattractant protein-1 (MCP-1), which induce VSMC 
proliferation and macrophage infiltration, respectively.49,51,52 
 REMNANT KIDNEY MODEL 
Various studies have investigated the effect of uric acid on multiple 
mechanisms of progressive renal injury. In the remnant kidney models 
Hyperuricemic remnant kidney rats (caused by addition of 2% oxonic acid to 
their diets) had higher BP, greater proteinuria, and higher serum 
creatinine.53,54 Addition of oxonic acid to cyclosporine treatment led to 
higher uric acid levels, more severe arteriolar hyalinosis, macrophage 
infiltration, and tubulointerstitial damage compared with rats that were 
treated with cyclosporine alone.55 Furthermore treatment of cyclosporine-
exposed  rats with allopurinol improves GFR55 and in human liver transplant 
patients who were receiving cyclosporine, treatment with allopurinol 
resulted in improved renal function.56 
 RECENT EPIDEMIOLOGY : A CHANGE IN PERSPECTIVE 
 Before 1990, only Khan et al.42 had reported that an increased serum 
uric acid is an independent risk factor for hypertension; however, it had been 
noted that 25 to 40% of adults with hypertension have serum uric acid > 6.5 
mg/ d1 and > 60% have a serum uric acid > 5.5 mg/dl34,35 and that there was 
a linear relationship between serum uric acid and systolic BP.57  Three 
reports  indicated that serum uric acid is an independent risk factor for 
hypertension, were published in the 1990s 40,41,44 and  five more were 
published in the past 4 years 43,45,58-60 including two in the first month of 
2005. The recent evaluation of a subset of the Framingham Heart study 
found that serum uric acid level was an independent predictor of 
hypertension and BP progression over as little as 4yrs.60  
Uric acid and essential hypertension in children 
In adolescents, the association between elevated serum uric acid and 
the onset of essential hypertension is even more striking. The Moscow 
Children’s Hypertension study found hyperuricemia ( > 8.0mg/d1) in 9.5% 
of children with normal BP, 49% of children with border line  hypertension 
and 73% of children  with moderate and the severe hypertension.61 
The Hungarian Children’s Health Study followed all 17,624 children 
who were born in Budapest in 1964 for 13 yrs and found that significant risk 
 factor for the development of hypertension were elevated heart rate, early 
sexual maturity, and hyperuricemia.62 
 Gruskin 63 compared adolescents (13 to 18 yrs of age) who had 
essential hypertension with age matched healthy control subject and who had 
normal BP. The hypertensive children had both elevated serum uric acid 
(mean> 6.5 mg/d1)and higher peripheral renin activity. 
Feig and Johnson observed that the mean serum uric acid level (+SD) 
in control subjects and children with white coat hypertension were nearly 
identical but slightly higher in secondary hypertension (4.3 ± 1.4 mg/dl, 
respectively; P = 0.80) but very high in children with primary hypertension 
(6.7 ± 1.3 mg/d1;P = 0.004). 54 There was a tight linear correlation between 
the serum uric acid levels and the systolic and diastolic BP in patients who 
were referred for evaluation of hypertension (r = 0.8 for systolic BP and r = 
0.6 for diastolic BP).39 
Among patient who were referred for evaluation of hypertension, a 
serum uric acid > 5.5 mg/d1 had an 89% positive predictive value for 
essential hypertension, whereas a serum uric acid level < 5.0 had a negative 
predictive value for essential hypertension of 96%. 39 
 The results from both animal and human studies strongly implicate 
uric acid as a factor in the onset of essential hypertension and as a potential 
contributor to the progression of renal injury. 
Evidence linking uric acid and hypertension 
1.  An elevated uric acid level consistently predicts the development of 
hypertension.40-44 
2.  An elevated uric acid level is observed in 25-60% of patients with 
untreated essential hypertension and in nearly 90% of adolescents with 
essential hypertension of recent onset.39 
3.  Raising the uric acid level in rodents results in hypertension with the 
clinical, hemodynamic, and histologic characteristics of 
hypertension.46 
4. Reducing the uric acid level with xanthine oxidase inhibitors lowers 
blood pressure in adolescents with hypertension of recent onset.64 
MECHANISM OF HYPERTENSION IN HYPERURICEMIA – RAT 
MODEL 
Most mammals have a low serum uric acid level because of the 
presence of uricase, a hepatic enzyme that degrades uric acid to allantoin. 
However in humans the uricase gene is mutated resulting in uric acid levels 
that are both higher and less regulatable than in other mammals. Interestingly 
 when mild hyperuricemia  was induced in rats by the administration of a 
uricase inhibitor, they became hypertensive . 
Hypertension in this model was mediated by 2 mechanisms. 
1. Uric acid induced renal vasoconstriction mediated by endothelial 
dysfunction with reduced NO levels and by activation of the renin-
angiotensin system. This hypertension type is salt resistant in that it 
occurs even in the presence of a low salt diet, and it responds to lowering 
of uric acid. 
2. Later however the hyperuricemia caused progressive renal microvascular 
disease (a lesion resembling arteriolosclerosis) and once sufficient 
narrowing of the arteriolar lumen occurs, a component of the 
hypertension become salt–driven; renal dependent and independent of 
uric acid levels. 
The identification of biological mechanism by which uric acid could 
cause hypertension in humans has led to a renewed interest in the role of uric 
acid in hypertension. Indeed, there are now 10 studies that have examined 
whether an elevated uric acid level predicts the development of 
hypertension, and all found uric acid predictive. 
The Bogalusa Heart study, found that uric acid levels in childhood 
predict the development of diastolic hypertension 10 years later.  The second 
 study, from the Framingham group60,also found uric acid of hypertension. 
This latter study is all more remarkable as it was performed in an older 
population (mean age 50) which they first eliminated 25% of their subjects 
because they already had hypertension or gout, thereby removing a large 
proportion of their target population. 
PROPOSED MECHANISM FOR URIC ACID MEDIATED 
HYPERTENSION IN HUMANS 27 
Excessive intake of fructose or purine-rich meats or exposure  to low 
does of lead may result in chronic hyperuricemia.  Mothers with high uric 
acid that are the result of diet or conditions such as pre-existing 
hypertension, obesity, or preeclampsia may transfer uric acid through the 
placenta to the fetus, which may ultimately contribute to intrauterine growth 
retardation (IUGR) and a reduction in nephron number. Among babies born 
with a low nephron number, hyperuricemia may develop in childhood 
because of genetic or environmental factors. Chronic hyperuricemia would 
stimulate the renin-angiotensin system and inhibit release of endothelial 
nitric oxide contributing to renal vasoconstriction and possibly increasing 
blood pressure. Persistent renal vasoconstriction may contribute to 
arteriolosclerosis and the development of salt sensitive hypertension , even if 
the hyperuricemia is corrected. 
 
 
 PROPOSED MECHANISM FOR URIC ACID MEDIATED 
HYPERTENSION IN HUMANS 
 
Maternal 
Factor
Placental 
Factor
Uric acid
IUGR 
Purine-rich or 
Fructose-heavy diet or 
Exposure to lead 
Genetic or 
Environmental factors Low nephron number 
Increased uric acid 
Increased renin and decreased 
Nitric Oxide 
Interstitial inflammation 
Microvascular inflammation 
Afferent arteriopathy 
Interstitial fibrosis 
Decreased nitric oxide and 
Increased ROS 
Vascular inflammation 
Proliferation of vascular 
smooth muscle cells with 
inhibition of endothelial cell 
growth 
Early stage 
Uric-acid induced vasoreactive hypertension 
Late stage 
Salt-sensitive kidney-dependent hypertension 
 Uric Acid as an Antioxidant : A Protective Factor in  
Cardiovascular Disease ? 
 
An important observation was that uric acid might function as an 
antioxidant, and possibly one of the most important antioxidants in 
plasma.70,72,73  Urate (the soluble form of uric acid in the blood) can scavenge 
superoxide, hydroxyl radical the singlet oxygen and can chelate transition 
metals. Peroxynitrite is a particularly toxic product formed by the reaction of 
superoxide anion with nitric oxide that can injure cells by nitrosylating the 
tyrosine residues (nitrotyrosine formation) of proteins. Uric acid can also 
block this reaction.67 
 Recently, Hink et al68 reported that uric acid might also prevent the 
degradation of extra cellular superoxide dismutase (SOD3), an enzyme 
critical in maintaining endothelial and vascular function. SOD3 is an 
extracellular enzyme that catalyzes the reaction of superoxide anion (o2-) to 
hydrogen peroxide (H2O2) . The removal of O2 by SOD3 prevents the 
reaction and inactivation by O2- of the important endothelial vasodilator, 
nitric oxide(NO).SOD3, by removing O2, therefore helps to maintain   NO 
levels and maintain endothelial function. Normally SOD3 is inactivated in 
the presence of H2O2, suggesting a feedback inactivation of the enzyme. 
However uric acid blocks SOD inactivation by H2O2 by regenerating SOD3 
 with the production of a urate radical. This latter radical although potentially 
a pro-oxidant, has been found to be markedly less reactive than classic 
oxidants and can be rapidly regenerated back to urate in the presence of 
ascorbate.69 
Ames et al70 hypothesized that the uricase mutation occurred during 
early hominoid evolution because the antioxidant action of uric acid may 
have provided an evolutionary advantage and that this may have accounted 
for the greater longevity of humans  and the great apes      compared with 
most other primates. The increase in serum uric acid in subjects with 
cardiovascular disease might therefore reflect a compensatory mechanism to 
counter the oxidative stress that occurs in these conditions. 71 However this 
does not readily explain why higher uric acid levels in patients with 
cardiovascular disease are generally associated with worse outcomes. 
 IV.MATERIALS AND METHODS 
 
         The study was conducted in 100 patients attending Government 
Royapettah Hospital Medicine Out Patient Department during the period 
from January 2009 to September 2010.The study was a cross-sectional study. 
The study group consisted of patients who fit into the criteria noted below. 
Written informed consent was obtained from all patients after explaining to 
them about the physical examination and investigation procedures that they 
will have to undergo during the study period.  
Ethical Committee approval was  obtained for the  study. 
 
A) INCLUSION CRITERIA: 
   1)  Newly detected hypertensive patients. 
   2)  Patients giving written consent for participating in the study. 
B) EXCLUSION CRITERIA: 
      1)  Age > 70 years. 
      2)  Hypertension duration > 6 months. 
      3)  Diabetes Mellitus. 
      4)  Congestive cardiac failure. 
      5)  Chronic Kidney Disease. 
      6)  Patients on diuretics, ACE inhibitors, AT  receptor antagonists. 
      7)  Secondary hypertension. 
       8)  Patients fulfilling the ATP III criteria for  Metabolic syndrome. 
      9)  Malignancy and lymphoproliferative disorders. 
     10)  Patients in hypertensive emergency. 
     11)  Patients with cerebrovascular disease.  
 
Definition of Metabolic syndrome  
 NCEP : ATP III 2001. 
There or more of the following: 
1.  Central obesity  
 Waist circumference > 102 cm (M) > 88 cm (F) 
2.  Hypertriglyceridemia 
 Triglycerides ≥ 150 mg / dl or specific medication. 
3.  Low HDL cholesterol : < 40 mg/dl (M) and < 50 mg / dl (F) or specific 
medication. 
4. Hypertension : Blood pressure ≥ 130 mm Hg systolic BP or ≥ 85 mm 
Hg diastolic BP or specific medication. 
5. Fasting plasma glucose ≥ 100 mg/dl or specific medication or 
previously diagnosed type 2 diabetes. 
 Three patients were lost to follow up, two had diastolic   dysfunction in 
ECHO, one had increased renal parenchymal echoes in USG abdomen.  
A written informed consent was obtained from all patients. History 
regarding the duration of hypertension, the medications being taken, co-
existing medical problems, and symptomatology suggestive of ischemic 
heart disease, transient ischemic attacks and that of renal involvement were 
documented. A detailed history of smoking (pack years / smoking index) and 
alcoholism (number of alcohol units per week was recorded; 1 alcohol unit = 
300 ml of beer, 100 ml of wine, or 30ml of liquor) was obtained. A family 
history of type 2 diabetes mellitus, systemic hypertension, cardiovascular 
and renal disease was noted. An overall clinical examination was done to 
exclude major co-morbidities. Examination of the heart and the peripheral 
pulses including the carotids were made. Abdominal examination was done 
to look for renal bruit. Central nervous system was examined to rule out 
focal neurological deficits.  
The blood pressure was measured at the time of enrollment. The 
average of their BP recorded in the last 6 months, if present was noted. With 
the patients in a seated position and after a 5-minute rest, BP was measured 
on the right arm and on the left arm with a mercury sphygmomanometer 
(cuff size 12.5 x 40 cm). The systolic pressure and diastolic pressure were 
 read to the nearest 2 mm Hg. Hypertension was defined according to JNC 
VII guidelines.  
The presence, type, and extent of hypertensive retinopathy was 
investigated in a darkened room and under pupil dilatation. Direct 
ophthalmoscopy was carried out with an ophthalmoscope. The first 
arteriovenous crossing at least one disc diameter from the disc in each 
quadrant was selected and assessed for the presence of focal arteriolar 
narrowing, haemorrhages, exudates, and papilledema. Retinal lesions were 
classified according to the Keith-Wagner-Barker classification.  
BMI was calculated with the following formula: 
BMI = weight (kg) / height2(m2). 
 
Waist circumference was measured as per ATP III guidelines. The 
standard laboratory testing for blood glucose, urea, serum creatinine,  
potassium was done. Serum lipid profile was done for all patients. These 
blood investigations were done with semi auto analyzer Merck 300. Urine 
was examined for protein and screened under the microscope for deposits. A 
baseline standard 12 lead ECG was taken. Left ventricular hypertrophy was 
calculated using the Romhilt-Estes scoring system (RE score) as shown 
below.: 
 Largest R/S wave in limb leads > 20mm or S wave in 
V1/V2 or R wave in V5/V6 > 30 mm 3 
Strain Pattern (without digoxin) 3 
Left atrial enlargement  3 
Left axis deviation  2 
QRS duration > 0.09 sec. 1 
Intrinsicoid deflection > 0.05 sec. 1 
     
A score greater than five was taken to indicate left ventricular hypertrophy.        
                
Microalbuminuria : 
All patients were subjected to a spot early morning urine sampling for 
microalbuminuria. The test was carried out by Immunoturbidometry. 
Microalbuminuria was present when urine albumin excretion was 30-300 
mcg/mg creatinine. 
Echocardiogram : 
Echocardiograms were obtained at rest with patients supine in the left 
lateral position, using standard parasternal and apical views. LV mass was 
derived using the formula described by Devereux and associates: 
 
 LV mass (grams) = 0.80 x 1.04 [(VSTd+LVIDd+PWTd)3- (LVIDd)3]+0.6 
• VSTd is ventricular septal thickness at end diastole 
• LVIDd is LV internal dimension at end diastole 
• PWTd is LV posterior wall thickness at end diastole 
LV mass was corrected for height2.7 (LVMI), and expressed in units of 
grams / meter (g /m2.7). The presence of left ventricular hypertrophy was 
defined for LVMI > 51 g/m2.7 in either gender74. 
Serum Uric Acid levels (SUA) : 
Serum uric acid was calculated using the enzymatic calorimetric test 
with the normal range for adult males being 3.6 – 7 mg/dl and for adult 
females being 2.3 – 6.1 mg/dl. Hyperuricemia was defined as SUA > 7 mg/dl 
in males and SUA > 6 mg/dl in females. 
Statistical analysis : 
All the datas in our study were analysed  with SPSS software. The 
statistical analysis was done using chi-square and two sample T test. 
 V. RESULTS 
 
 
1. Age Distribution : 
 
Age Group Numbers 
≤ 35 20 
36 – 45 36 
46 – 55 20 
≥ 56 18 
 
 
2. Sex Distribution : 
 
 
Sex Numbers (%) 
Male 54 (57.4%) 
Female 40 (42.6%) 
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3.  Menopausal Status : 
 
Menopausal State Numbers (%) 
Attained Menopause 16 (40%) 
Not Attained Menopause 24 (60%) 
 
 
4.  Blood Pressure Distribution : 
 
Average Blood Pressure Numbers (%) 
Systolic 140 – 160 or Diastolic 90 - 100 69 (73.4%) 
Systolic > 160 or Diastolic > 100 25 (26.6%) 
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5.  Smoking or Alcohol Habits : 
 
 
Habits  Numbers (%) 
Yes 32 (34%) 
No 62 (66%) 
Smokers only 9 (0.1%) 
Alcoholics only 11 (11.7%) 
Both 12 (12.8%) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
6. Family History of SHT / DM / CHD  : 
 
 
Family History Numbers (%) 
Positive 40 (42.5%) 
Negative 54 (57.5%) 
 
  
7.  Body Mass Index Distribution : 
 
 
Characteristics  Numbers (%) 
BMI (mean) 24.175 
BMI (range) 21.6 - 29.14 
BMI (25 – 30) Overweight  23 (24.5%) 
 
 
8.  Waist Circumference Distribution : 
 
 
Characteristics  Numbers (%) 
Waist Circumference (mean) 89.09 cm 
Waist Circumference (range) 80 – 106 cm 
Waist Circumference > 90 cm 
(males) 
 
35 (64.8% of males) 
Waist Circumference > 80 cm 
(Females) 
 
34 (85% of females) 
 
 
9.  Lipid Distribution : 
 
 
Characteristics  Distribution  
Total Cholesterol (mean) 195.11 
Total Cholesterol (range) 150 – 234 
HDL Cholesterol (mean) 47.28 mg/dl  
HDL Cholesterol (range) 36-56 
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10.  Hypertensive retinal changes : 
 
 
 Keith Wagner grading Numbers (%) 
Grade I 16 (17%) 
Grade II 69 (73.4%) 
Grade III 9 (9.6%) 
Grade IV 0 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
11.  ECG evidence of left ventricular hypertrophy : 
 
 
Romhilt Estes Score Numbers (%) 
< = 5 83 (88.3%) 
> 5 11 (11.7%)  
 
9.6% 
73.4% 
17% 
  
12.  Microalbuminuria : 
 
 
Characteristics  Numbers (%) 
Microalbuminuria present 27 (28.7%) 
 
 
13.  Left Ventricular Mass Index Distribution : 
 
 
Characteristics  Numbers (%) 
LV mass index (mean) 51 ± 0.503 
LV mass index (range) 40 – 65 
LV mass index > 51 
(left ventricular hypertrophy) 
48 (51.1%) 
LV mass index ≤ 51 46 (48.9%) 
 
 
14.  Serum Uric Acid Distribution : 
 
 
Characteristics  Numbers (%) 
Serum Uric Acid Levels (mean) 5.89 
Serum Uric Acid Levels (range) 3 – 8.2 
Uric acid > 6 (females) 12 ( 30% of females) 
Uric acid > 7 (males) 17 (31.5% of males) 
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 CORRELATION OF URIC ACID LEVELS WITH     
VARIOUS PARAMETERS 
 
TABLE 1 : CORRELATION OF AGE AND URIC ACID 
 
 
 URIC 
ACID N Mean 
Std. 
Deviation 
Std. Error 
Mean 
AGE HIGH 29 47.07 10.166 1.888 
NORMAL 65 43.58 9.639 1.196 
 
   URIC ACID  
   NORMAL HIGH Total 
AGE GROUP ≤ 35 Count 14 6 20 
% within URIC 
ACID 
21.5% 20.7% 21.3% 
% of Total 14.9% 6.4% 21.3% 
36-45 Count 29 7 36 
% within URIC 
ACID 
44.6% 24.1% 38.3% 
% of Total 30.9% 7.4% 38.3% 
46-55 Count 11 9 20 
% within URIC 
ACID 
16.9% 31.0% 21.3% 
% of Total 11.7% 9.6% 21.3% 
≥ 56 Count 11 7 18 
% within URIC 
ACID 
16.9% 24.1% 19.1% 
% of Total 11.7% 7.4% 19.1% 
 Total Count 65 29 94 
% within URIC 
ACID 
100.0% 100.0% 100.0% 
% of Total 69.1% 30.9% 100.0% 
P= 0.201  NOT SIGNIFICANT. 
 
 TABLE 2: CORRELATION OF SEX AND URIC ACID 
 
   URIC ACID  
   NORMAL HIGH Total 
SEX F Count 28 12 40 
% within URIC 
ACID
43.1% 41.4% 42.6% 
% of Total 29.8% 12.8% 42.6% 
M Count 37 17 54 
% within URIC 
ACID 
56.9% 58.6% 57.4% 
% of Total 39.4% 18.1% 57.4% 
 Total Count 65 29 94 
% within URIC 
ACID 
100.0% 100.0% 100.0% 
% of Total 69.1% 30.9% 100.0% 
P= 0.878  NOT SIGNIFICANT.  
 
TABLE 3: CORRELATION OF MENOPAUSE AND URIC ACID 
 
   URIC ACID  
   NORMAL HIGH Total 
MENOPAUSE NO Count 17 7 24
% within URIC ACID 60% 58.3% 
% of Total 42.5 17.5% 60%
YES Count 11 5 16
% within URIC ACID 40% 41.66% 
% of Total 27.5% 12.5% 40%
 Total Count 28 12 40
% within URIC ACID 100.0% 100.0% 100.0%
% of Total 70% 30% 100.0%
 
P= 0.8327   NOT SIGNIFICANT. 
 
Age, Sex, Menopausal Status did not correlate significantly with uric acid. 
 
 
 
 TABLE 4:  CORRELATION OF SMOKING WITH URIC ACID 
 
 
   URIC ACID  
   NORMAL HIGH Total 
SMOKING Absent Count 54 19 73
% within URIC 
ACID 
83.1% 65.5% 77.7%
% of Total 57.4% 20.2% 77.7%
Present Count 11 10 21
% within URIC 
ACID 
16.9% 34.5% 22.3%
% of Total 11.7% 10.6% 22.3%
 Total Count 65 29 94
% within URIC 
ACID 
100.0% 100.0% 100.0%
P= 0.059  NOT SIGNIFICANT. 
 
TABLE 5 :CORRELATION OF ALCOHOL WITH URIC ACID 
 
   URIC ACID  
   NORMAL HIGH Total 
ALCOHOL Absent Count 52 19 71 
% within URIC ACID 80.0% 65.5% 75.5% 
% of Total 55.3% 20.2% 75.5% 
Present Count 13 10 23 
% within URIC ACID 20.0% 34.5% 24.5% 
% of Total 13.8% 10.6% 24.5% 
 Total Count 65 29 94 
% within URIC ACID 100.0% 100.0% 100.0% 
% of Total 69.1% 30.9% 100.0% 
 
P= 0.131 NOT SIGNIFICANT. 
 
Smoking and Alcoholism did not correlate significantly with uric acid. 
 
 TABLE 6 : CORRELATION OF BLOOD PRESSURE WITH URIC 
ACID 
 
 URIC 
ACID N Mean
Std. 
Deviation 
Std. Error 
Mean 
SYSTOLIC BLOOD 
PRESSURE 
HIGH 29 158.48 11.028 2.048
NORMAL 65 154.43 9.556 1.185
DIASTOLIC BLOOD 
PRESSURE 
HIGH 29 96.14 6.717 1.247
NORMAL 65 94.95 5.636 .699
 
SYST. BP P= 0.160 
 
DIAS. BP P= 0.337  BOTH NOT SIGNIFICANT. 
 
 
TABLE 7 : CORRELATION OF BMI WITH URICACID 
 
 URIC 
ACID N Mean Std. Deviation
Std. Error 
Mean 
BMI HIGH 29 23.90 1.231 .229
NORMAL 65 24.45 1.818 .225
 
P= 0.142 NOT SIGNIFICANT. 
 
 
TABLE 8 : CORRELATION OF WAIST  CIRCUMFERENCE WITH 
URIC ACID 
 
 URIC 
ACID N Mean 
Std. 
Deviation 
Std. Error 
Mean 
WAIST  HIGH 29 89.14 6.463 1.200
NORMAL 65 89.05 5.914 .733
 
P= 0.951 NOT SIGNIFICANT. 
 
 
 
 TABLE 9 : CORRELATION OF TOTAL CHOLESTEROL WITH 
URIC ACID 
 
 
URIC 
ACID N Mean
Std. 
Deviation 
Std. Error 
Mean
TOTAL 
CHOLESTEROL 
HIGH 29 194.97 23.603 4.383
NORMAL 65 195.25 20.588 2.554
 
P= 0.954 NOT SIGNIFICANT. 
 
TABLE 10 : CORRELATION OF TGL WITH URIC ACID 
 
 
 
URIC 
ACID N Mean 
Std. 
Deviation Std. Error Mean
TGL HIGH 29 145.66 13.468 2.501
NORMAL 65 146.46 15.478 1.920
 
P= 0.809 NOT SIGNIFICANT. 
 
SBP, DBP, BMI, waist circumference, Total Cholesterol, TGL did not correlate 
significantly with uric acid. 
 
TABLE 10 : CORRELATION OF ECG WITH URIC ACID 
 
 
   
URIC ACID  
NORMAL HIGH Total 
ECG LVH (–) Count 59 21 80 
% within URIC ACID 90.8% 72.4% 85.1% 
% of Total 62.8% 22.3% 85.1% 
LVH (+) Count 6 8 14 
% within URIC ACID 9.2% 27.6% 14.9% 
% of Total 6.4% 8.5% 14.9% 
 Total Count 65 29 94 
% within URIC ACID 100.0% 100.0% 100.0% 
% of Total 69.1% 30.9% 100.0% 
P=0.021 SIGNIFICANT. 
 
 TABLE 11 : CORRELATION OF LVMI WITH URIC ACID 
  
   URIC ACID  
   NORMAL HIGH Total 
LVMI ≤ 51 Count 43 3 46 
% within URIC ACID 66.2% 10.3% 48.9% 
% of Total 45.7% 3.2% 48.9% 
> 51 Count 22 26 48 
% within URIC ACID 33.8% 89.7% 51.1% 
% of Total 23.4% 27.7% 51.1% 
 Total Count 65 29 94 
% within URIC ACID 100.0% 100.0% 100.0% 
% of Total 69.1% 30.9% 100.0% 
 
P < 0.001 SIGNIFICANT 
 
TABLE 12 : CORRELATION OF MICROALBUMINURIA WITH 
URIC ACID 
 
   URIC ACID  
   NORMAL HIGH Total 
MICRO Absent Count 61 6 67 
% within URIC ACID 93.8% 20.7% 71.3% 
% of Total 64.9% 6.4% 71.3% 
Present Count 4 23 27 
% within URIC ACID 6.2% 79.3% 28.7% 
% of Total 4.3% 24.5% 28.7% 
 Total Count 65 29 94 
% within URIC ACID 100.0% 100.0% 100.0% 
% of Total 69.1% 30.9% 100.0% 
 
P < 0.001 SIGNIFICANT. 
 
ECG, LVMI, Microalbuminuria correlate significantly with uric acid. 
 TABLE 13 : CORRELATION OF RETINOPATHY WITH URIC 
ACID 
 
   URIC ACID  
   NORMAL HIGH Total 
KW 1 Count 14 2 16 
% within URIC ACID 21.5% 6.9% 17.0% 
% of Total 14.9% 2.1% 17.0% 
2 Count 45 24 69 
% within URIC ACID 69.2% 82.8% 73.4% 
% of Total 47.9% 25.5% 73.4% 
3 Count 6 3 9 
% within URIC ACID 9.2% 10.3% 9.6% 
% of Total 6.4% 3.2% 9.6% 
 
 
 
 
Total Count 65 29 94 
% within URIC ACID 100.0% 100.0% 100.0% 
% of Total 69.1% 30.9% 100.0% 
 
P= 0.217 NOT SIGNIFICANT.  
 
Hypertensive retinopathy did not correlate significantly with uric acid. 
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 VI. DISCUSSION  
 
  
Our study demonstrates that serum uric acid levels are associated with 
preclinical TOD, namely LVH and microalbuminuria, in newly detected 
hypertensive patients. Similarly, there are few studies done on association 
between serum uric acid levels and presence and degree of target organ 
damage in essential hypertension. We will compare our study with two other 
studies namely an Italian study done by Francesca Viazzi et al 65,66 and 
another study done by C Tsioufis, D Chatsis75 in Athens university. Similar 
studies have not been undertaken in our country. 
 
IA. Comparative Descriptive statistics (Age; Sex) 
 
Parameters Italian Study (n=425) 
Athens Study 
(n=842) 
Current Study
(n=94) 
Sex : Male 
         Female 
265 407 54 
160 435 40 
Age (yrs) 47 ± 9 52.94 ± 11.57 45.3 ±  9.9 
Premenopausal (nos.) NA NA 24 
Postmenopausal (nos.) NA NA 16 
 
 IB.  Comparative Descriptive statistics  
(family history, smoking, BMI, lipid profile) 
 
Parameters Italian Study (n=425) 
Athens Study 
(n=842) 
Current 
Study 
(n=94) 
Family history (%) 52 NA 42.5 
Smokers (%) NA 31.1 22.3 
Alcohol (%) NA NA 24.5 
BMI (kg/m2) 26.4  ±  3.6 28.51 ±  4.09 24.17  ± 1.52 
Total Cholesterol 
(mg/dl) 
211.13  ±  1.11 222.14 ± 40.46 195.11 ± 22.09 
HDL Cholesterol 
(mg/dl) 
52.97 ± 0.36 48.36  ±  9.67 47.28  ±  4.65 
 
 
The average age of patients in our study was 45.3 ,which was 
comparable to the Italian study. In the Athens study the average age was 
52.94, a little higher than our study. Our study also demarcated the female 
population into the premenopausal and the postmenopausal groups to study 
if there existed any significant correlation with SUA values with menopause 
but there was none. A positive family history in the Italian study was slightly 
higher when compared to our study. This could be due to the lack awareness 
and accessibility of pre-symptomatic health screening as well as lack of 
knowledge regarding the symptomatology of various cardiovascular, renal 
events in our population. About 22.3% of the study population were smokers 
in our study where as it was around 31.1% in Athens study. The BMI among 
 our study population was lower when compared with the other two study 
populations. This could probably be explained by the high prevalence of 
malnutrition, modified life style and food habits in our country. The mean 
total cholesterol was highest in the Athens study group, followed by the 
Italian study population. Further the HDL cholesterol was highest among the 
Italian study group. The prevalence of metabolic syndrome in the Italian 
study group was 21%. In our study, patients were selected such that they 
don’t fall into the criteria for metabolic syndrome according to ATP III 
guidelines. But the individual components of metabolic  syndrome were not 
compared in our study. 
 
IC. Comparative Descriptive statistics : 
 
Parameters Italian 
Study 
(n=425) 
Athens 
Study 
(n=842) 
Current 
Study 
(2010) 
Uric acid (mg/dl) 5.14 ± 0.13 5.1 ± 0.1 5.4 ± 1.57 
LVH - ECG evidence (%) 13% NA 14.9 
LV mass index 52 ± 2.8 53 ± 0.7 51 ± 0.503 
LVH – ECHO evidence 
(%) 
43% 36.2% 51.1 
 
The mean uric acid levels were comparable among all three population. 
Electrocardiographic evidence of LVH was found in 14.9% in our study, 
while echocardiographic evidence was present in 51.1%. The figures are 
 slightly higher when compared with the Italian study(43%). In the Athens 
study group, the ECHO evidence of LVH was found in 36.2%. The mean 
LV mass index was comparable between all three populations. 
 
II. Comparative Descriptive statistics : 
 
Parameters Italian Study 
(n=425) 
Athens Study 
(n=842) 
Current Study 
(2010) 
Age Not Sig.* Not Sig. Not Sig. 
Gender NA Not Sig. Not Sig. 
SBP Not Sig. P < 0.05 Not Sig. 
BMI P=0.003 P < 0.05 P = 0.142 
Total Cholesterol Not Sig. NA Not Sig. 
Microalbuminuria P = 0.02 P < 0.001 P < 0.001 
LV mass index P = 0.002 P < 0.05 P < 0.001 
* Not Sig. – Not Significant. 
 
Serum uric acid values were correlated with various variables that 
affected the target organ damage in hypertensive population. In all the three 
study groups, age and sex did not have any significant effect on the uric acid 
levels. Among the Athens study group, there was a positive correlation  
between SBP and serum uric acid values where as in our study and Italian 
study, the correlation of SBP and serum uric acid levels was not significant. 
However we will have to emphasize the fact that target organ dysfunction 
primarily depends on adequacy of blood pressure control. This has been 
emphasized by previous studies by Francesca et al.68 The role of increased 
 pulse pressure in the context of cardiovascular risk assessment and 
stratification is currently receiving growing attention. Furthermore, elevated 
pulse pressure values, measured both in office and by 24-hr ambulatory 
monitoring, have been linked to the presence of sub-clinical cardiovascular 
damage, i.e. left ventricular hypertrophy, increased carotid wall thickness 
and microalbuminuria as well as to structural changes in peripheral 
vasculature. It has been suggested that high pulse pressure levels reflect the 
degree of stiffness of the arterial tree, regardless of whether they are caused 
by increased systolic blood pressure (SBP) and/or reduced diastolic blood 
pressure (DBP).  
In our study, it has been noted that serum uric acid levels did not 
correlate significantly with BMI, total cholesterol, waist circumference 
suggesting SUA as an independent marker of cardiovascular and renal 
abnormalities. Similarly in the Italian study, total cholesterol did not 
correlate significantly with serum uric acid. But BMI correlated significantly 
with serum uric acid values in both Italian and Athens study. 
Further in our study there was a significant correlation of serum uric 
acid levels with target organ dysfunction such as microalbuminuria, LV 
mass index but not with hypertensive retinal changes. These findings were 
similar to the Italian study, which also reported a strong association between 
serum uric acid levels and pre-clinical organ dysfunction. In the Athens 
 study, there was a significant correlation with SUA values and 
microalbuminuria. But when comparing LVH(+) group with LVH(-) one, 
although a trend for higher values of microalbuminuria was noted, there was 
no significant correlation with SUA values. 
In studies it was observed that the degree of blood pressure control 
had a negative correlation with the waist circumference. Insulin resistance 
can explain this relation and in the context of primary hypertension, mild 
hyperuricemia is often a feature of insulin resistance and the metabolic 
syndrome. The current study however did not show any correlation between 
the metabolic syndrome components (waist circumference, dyslipidemia) 
and uric acid levels. However a formal comparison was not done between 
patients who had metabolic syndrome and those who did not, as we have 
excluded patients fitting into metabolic syndrome. The results suggested that 
uric acid might be implicated in the early pathogenetic stages of 
cardiovascular damage. They also provide a pathophysiological rationale to 
at least partly account for the association of uric acid to cardiovascular 
events and mortality in hypertensive patients. In fact, sub clinical TOD 
represents an intermediate step between exposure to risk factors and 
occurrence of overt cardiovascular disease and has previously been shown to 
be a strong predictor of major events.  
 Several mechanisms have been proposed to account for the association 
between SUA and cardiovascular and renal abnormalities, and include: (1) 
increased uric acid production to counteract oxidative stress and endothelial 
damage in the context of the atherosclerotic process (2) the severity of 
hypertension itself; and (3) a subtle reduction in glomerular filtration rate 
leading to impaired renal uric acid clearance. The issue of mild 
hyperuricemia and cardiovascular disease has been getting more and more 
attention since anti-hypertensive agents were shown to possibly induce 
subtle but significant changes in uric acid, which could have an impact on 
their ability to provide cardiovascular and renal protection. In conclusion the 
present study showed that increased SUA was a marker of preclinical TOD 
in a population of patients with primary hypertension.  
 VII. SUMMARY  
 
 
• Age, sex, menopausal state did not have any effect on serum uric 
acid levels. 
• Alcohol and smoking habits did not influence the serum uric acid 
values significantly. 
• Family history of diabetes, hypertension and coronary artery 
disease were not associated significantly with serum uric acid 
values. 
• Systolic and diastolic blood pressures had no significant influence 
on serum uric acid values. 
• BMI, waist circumference, total cholesterol, TGL, HDL did not 
correlate significantly with serum uric acid values. 
• Uric acid values correlated significantly with target organ indices 
such as electrocardiographic and echocardiographic evidence of 
LVH, microalbuminuria. 
• Uric acid values did not correlate significantly with hypertensive 
retinal changes. 
 
 VIII. CONCLUSION 
 
The role of serum uric acid as an independent risk factor for 
cardiovascular and renal morbidity is controversial. However studies have 
shown that SUA is often elevated in hypertension and can indicate impaired 
renal function even before development of proteinuria.76,77 The present study 
aimed to evaluate the correlation between SUA levels and the presence of 
pre-clinical target organ damage in hypertensive population. 100 patients 
with newly or recently detected hypertension were studied and assessed for 
target organ damage indices. SUA levels correlated significantly with target 
organ damage indices such as LVMI and microalbuminuria but not with 
hypertensive retinal changes. Further we will have to note that even after 
excluding patients with metabolic syndrome, SUA correlated significantly 
with TOD suggesting that serum uric acid may be a predictor of 
cardiovascular and renal morbidity in hypertensive patients. However further 
studies have to be done to confirm the role of SUA as a predictor of target 
organ damage. 
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 PROFORMA 
NAME :     AGE:  SEX:  O.P. NO: 
OCCUPATION:    ADDRESS: 
HISTORY :            - Headache  - Breathlessness 
- Giddiness  - Palpitation 
- Chest pain  - Edema legs 
PAST HISTORY : 
1) HT-YES/NO       DURATION :  Rx DETAILS 
2) DM-YES/NO       DURATION :  Rx DETAILS 
3) CKD- YES/NO       DURATION :  Rx DETAILS 
4) CCF- YES/NO       DURATION :  Rx DETAILS 
DRUG HISTORY : YES/NO     CVA - YES/NO  GOUT- YES/NO 
CAD-YES/NO       MALIGNANCY : YES/NO 
THYROID DISORDER - YES/NO 
PERSONAL HISTORY : 
DIET : SALT RESTRICTED : YES/NO 
SMOKING : YES/NO            ALCOHOL : YES/NO          
   TOBACCO : YES/NO 
 GENERAL EXAMINATIONS : 
HT :                     WT:                   BMI:                     WAIST CIRCUM. 
ANAEMIA 
CYANOSIS 
CLUBBING 
PEDAL EDEMA 
ICTERUS 
GENERALISED LYMPHADENOPATHY 
THYROID 
VITALS : PR 
                  BP -      LEFT ARM   RIGHT ARM 
  1. 
  2. 
  MEAN : 
    Higher of the mean: 
SYSTEMIC EXAMINATION : 
CVS: 
RS : 
ABD: 
CNS: 
FUNDUS EXAMINATION : 
 INVESTIGATIONS : 
1. COMPLETE HAEMOGRAM  
2. URINE – ALBUMIN    
                SUGAR     
                DEPOSITS     
3. FASTING BLOOD SUGAR - 
4. BLOOD UREA   - 
5. SERUM CREATININE  - 
6. SERUM URIC ACID  - 
7. LIPID PROFILE   - TOTAL CHOLESTROL 
     TRIGLYCERIDES 
     HDL 
     LDL   
     VLDL 
8. LIVER FUNCTION  TEST  SERUM BILIRUBIN 
      TRANSAMINASES, 
      ALKALINE PHOSPHATASE 
      SERUM ALBUMIN AND 
      GLOBULIN 
9. THYROID FUNCTION TESTS - T3, T4, TSH 
10. ECG 
11. ECHO 
 ABBREVIATIONS 
 
BP        -  Blood Pressure. 
SBP     -  Systolic Blood Pressure. 
DBP        -  Diastolic Blood Pressure. 
HT        -  Hypertension. 
SUA    -  Serum Uric Acid. 
SD           -  Standard Deviation. 
MS          -  Metabolic Syndrome. 
TOD       -  Target Organ Damage. 
BMI       -  Body Mass Index. 
CHD     -  Coronary Heart Disease. 
CHF        -  Congestive Heart Failure. 
ECHO      -  Echocardiography. 
USG             -  Ultrasonogram. 
NCEP      -  National Cholesterol Education Program. 
ATP       -  Adult Treatment Panel. 
LVMI - Left ventricular myocardial index. 
LVH - Left ventricular hypertrophy. 
ECG - Electrocardiography. 
RE Score - Romhilt Estes Score. 
 KW  - Keith-Wagner-Barker Staging. 
ESRD - End Stage Renal Disease. 
JNC  - Joint National Committee. 
CVD  - Cardiovascular disease. 
GFR  - Glomerular Filtration Rate. 
IUGR  - Intrauterine Growth Retardation. 
ROS  - Reactive Oxygen Species. 
SOD  - Superoxide Dismutase. 
ACE  - Angiotensin-converting enzyme. 
AT  - Angiotensin. 
LV  - Left Ventricle. 
HDL  - High Density Lipoprotein. 
TGL  - Triglyceride. 
NA  - Not Available. 
 
 
 
 
 
